Literature DB >> 12185103

Higher testosterone dose impairs sperm suppression induced by a combined androgen-progestin regimen.

M Cristina Meriggiola1, Antonietta Costantino, William J Bremner, Antonio M Morselli-Labate.   

Abstract

In this study we compared the effects of high-dose and low-dose testosterone enanthate (TE) administered with the same dose of cyproterone acetate (CPA). Eighteen men aged 21-45 were treated with CPA 5 mg/day and with TE 100 mg/week (n = 9; CPA-5-100) or TE 200 mg/week (n = 9; CPA-5-200) for 16 weeks. Semen analyses were performed every 2 weeks; physical examination and chemistry, hematology, gonadotropin, and testosterone measurements were performed every 4 weeks. At week 16 of treatment, sperm counts were significantly more suppressed in the CPA-5-100 group than in the CPA-5-200 group. Sperm counts returned to baseline in all subjects after hormone administration ceased. No difference in gonadotropin levels was found at any time between the 2 groups. During the treatment phase, testosterone levels were significantly higher in the CPA-5-200 group than in the CPA-5-100 group. The present study confirms that CPA/TE administration induces profound sperm suppression. An increase in the dose of androgen resulted in less profound sperm suppression despite no difference in gonadotropin suppression. These data suggest that high testosterone levels can maintain sperm production in men.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12185103

Source DB:  PubMed          Journal:  J Androl        ISSN: 0196-3635


  11 in total

1.  Short-term modification of sex hormones is associated with changes in ghrelin circulating levels in healthy normal-weight men.

Authors:  A Gambineri; U Pagotto; R De Lasio; M C Meriggiola; A Costantino; L Patton; C Pelusi; G Pelusi; R Pasquali
Journal:  J Endocrinol Invest       Date:  2005-03       Impact factor: 4.256

2.  Hormonal control of inhibin B in men.

Authors:  V A Giagulli; D Carbone
Journal:  J Endocrinol Invest       Date:  2006-09       Impact factor: 4.256

Review 3.  Recent methodological advances in male hormonal contraception.

Authors:  Peter Y Liu; Ronald S Swerdloff; Christina Wang
Journal:  Contraception       Date:  2010-05-21       Impact factor: 3.375

4.  Nasal steroid perspective: knowledge and attitudes.

Authors:  Cemal Cingi; Murat Songu
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-11-21       Impact factor: 2.503

Review 5.  Advances in male contraception.

Authors:  Stephanie T Page; John K Amory; William J Bremner
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

6.  Determinants of the rate and extent of spermatogenic suppression during hormonal male contraception: an integrated analysis.

Authors:  Peter Y Liu; Ronald S Swerdloff; Bradley D Anawalt; Richard A Anderson; William J Bremner; Joerg Elliesen; Yi-Qun Gu; Wendy M Kersemaekers; Robert I McLachlan; M Cristina Meriggiola; Eberhard Nieschlag; Regine Sitruk-Ware; Kirsten Vogelsong; Xing-Hai Wang; Frederick C W Wu; Michael Zitzmann; David J Handelsman; Christina Wang
Journal:  J Clin Endocrinol Metab       Date:  2008-02-26       Impact factor: 5.958

Review 7.  Testosterone replacement therapy and cardiovascular risk.

Authors:  Thiago Gagliano-Jucá; Shehzad Basaria
Journal:  Nat Rev Cardiol       Date:  2019-09       Impact factor: 32.419

Review 8.  Male hormonal contraception: hope and promise.

Authors:  Katarzyna Piotrowska; Christina Wang; Ronald S Swerdloff; Peter Y Liu
Journal:  Lancet Diabetes Endocrinol       Date:  2016-02-23       Impact factor: 44.867

9.  Hormonal, chemical and thermal inhibition of spermatogenesis: contribution of French teams to international data with the aim of developing male contraception in France.

Authors:  Jean-Claude Soufir
Journal:  Basic Clin Androl       Date:  2017-01-13

10.  Suppression of spermatogenesis by testosterone undecanoate-loaded injectable in situ-forming implants in adult male rats.

Authors:  Xiao-Wei Zhang; Chong Zhang; Wei Zhang; Dan Yang; Shu Meng; Ping Wang; Jing Guo; Dan-Hua Liu
Journal:  Asian J Androl       Date:  2016 Sep-Oct       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.